Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam.
Vivace Therapeutics Receives FDA Orphan Drug Designation for VT3989 for Mesothelioma Treatment
Vivace Therapeutics, a company that develops cancer treatments, announced on July 30, 2025, that the U.S. Food and Drug Administration (FDA) has granted its experimental
